Alto Neuroscience, Inc.
NYSE:ANROBiotechnology
+$0.40 today
- Market cap
- $1.04B
- Beta
- 1.25
- P/E (TTM)
- -9.8
- EPS (TTM)
- -$2.26
Volume 0.99M
Average 0.34M
ANRO Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
Alto Neuroscience, Inc.NYSE: ANRO
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization growth accelerates
Q1 FY2026 depreciation & amortization of $184K rose 7.6% year over year, ahead of the +5.0% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 17.2% from the prior quarter. Over 3 fiscal years it compounded at +24.6% a year.
Context
- Depreciation & amortization increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +7.6% holds above the trailing-twelve-month pace of +5.0%.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2025
- 661K USD
- Year-over-year change
- +31.7%
- 4-year CAGR
- +46.1%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 661K | +31.7% |
| FY2024 | 2024-12-31 | 502K | +34.6% |
| FY2023 | 2023-12-31 | 373K | +9.1% |
| FY2022 | 2022-12-31 | 342K | +135.9% |
| FY2021 | 2021-12-31 | 145K | — |
Depreciation & Amortization vs competitors
How ANRO compares with its peers on the latest reported figures
- Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +5.0% is the 4th highest of 10, against a peer median of +0.0%.
- Over three fiscal years its annual growth of +24.6% compares with a peer median of +2.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $19.68M USD | -2.6% | +2.9% | 28.9% | |
| LTM Mar 2026 | $12.36M USD | +53.3% | -27.5% | — | |
| LTM Mar 2026 | $3.44M USD | -15.5% | +19.5% | 89.4% | |
| LTM Mar 2026 | $2.93M USD | -1.6% | -0.7% | 1.4% | |
| LTM Mar 2026 | $1.77M USD | +61.3% | +8.0% | — | |
| LTM Mar 2026 | CHF 1.61M CHF | -27.3% | +2.0% | 43.6% | |
| LTM Mar 2026 | $605K USD | +5.0% | +24.6% | — | |
| LTM Mar 2026 | $577.79K USD | — | +4.5% | 62.7% | |
CTNMContineum Therapeutics, Inc. Class A Common Stock | LTM Mar 2026 | $328K USD | +19.3% | -0.6% | — |
| LTM Mar 2026 | $326K USD | +0.0% | +3.2% | — | |
| LTM Mar 2026 | $257.68K USD | +3.1% | -0.9% | — | |
| Peer median (excluding ANRO) | — | +0.0% | +2.4% | 43.6% | |
Competitors are the stored peer set for ANRO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 210K | 0 | 0 | 0 | 0 |
| Cost of Revenue | 145K | 342K | 0 | 502K | 661K |
| Gross Profit | 65K | (342K) | 0 | (502K) | (661K) |
| Gross Margin | 31.0% | — | — | — | — |
| Research & Development | 8.37M | 23.69M | 30.29M | 47M | 45.62M |
| Selling, General & Admin | 3.75M | 5.16M | 7.52M | 21.61M | 20.75M |
| Operating Expenses | 12.12M | 28.85M | 37.81M | 68.11M | 65.7M |
| Depreciation & Amortization | 145K | 342K | 373K | 502K | 661K |
| EBITDA | (9.04M) | (27.37M) | (34.56M) | (62.3M) | (60.11M) |
| EBITDA Margin | -4305.7% | — | — | — | — |
| Operating Income | (12.06M) | (29.19M) | (37.81M) | (68.61M) | (66.36M) |
| Operating Margin | -5741.0% | — | — | — | — |
| Interest Income | 2K | 114K | 2.35M | 8.85M | 6.6M |
| Interest Expense | 0 | 0 | 1.37M | (1.38M) | 2.47M |
| Other Income / Expenses | 2.87M | 1.48M | 1.5M | 7.18M | 3.13M |
| Income Before Tax | (9.19M) | (27.71M) | (36.31M) | (61.43M) | (63.24M) |
| Pre-Tax Margin | -4374.8% | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (9.19M) | (27.71M) | (36.31M) | (61.43M) | (63.24M) |
| Net Margin | -4374.8% | — | — | — | — |
| EPS (Basic) | (0.36) | (1.08) | (1.35) | (2.50) | (2.19) |
| EPS (Diluted) | (0.36) | (1.08) | (1.35) | (2.50) | (2.19) |
| Weighted Avg Shares | 25.57M | 25.57M | 26.88M | 24.6M | 28.85M |
| Weighted Avg Shares (Diluted) | 25.57M | 25.57M | 26.88M | 24.6M | 28.85M |
Alto Neuroscience, Inc.
NYSE:ANRO
Intrinsic Alpha fair value
Locked
Current Price
$25.91
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.